FDA Officials Say Potency Problems Main Reason for NTI Drug Recalls
This article was originally published in The Gold Sheet
Executive Summary
FDA officials said that use of quality by design as well as “equivalence by design” will help drug manufacturers develop better generic substitutions of narrow therapeutic index (NTI) drugs to address the high rate of recalls associated with these products due to potency problems.
You may also be interested in...
ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.